Elderly are more likely to suffer from hypertension and heart disease. But, they do not respond to current therapies to reduce blood pressure and the factors that drive age-related hypertension are poorly understood.
In this issue of JCI Insight, researchers led by Iris Jaffe of Tufts Medical Center provide evidence that age-related reductions of a microRNA (miR-155) underlie age-associated hypertension.
‘microRNA (miR-155) could be a biomarker for hypertension and also a therapeutic target for age-related hypertension.
Mice that lack mineralocorticoid receptors in smooth muscle cells, which regulate blood pressure, are protected from developing high blood pressure as they age.
Jaffe and colleagues determined that compared to aged wild-type mice, aged animals lacking mineralocorticoid receptors have elevated levels of miR-155, less oxidative stress, and fewer hypertensive characteristics.
Moreover, restoration of miR-155 in aged wild-type mice improved blood pressure parameters. Importantly, in a small cohort of healthy older adults treated with a mineralocorticoid receptor inhibitor, reduced levels of miR-155 were associated with beneficial changes in blood pressure.
Together, these results indicate that miR-155 should be further explored as a biomarker and therapeutic target for age-related hypertension.